The Green Cross Corporation

Samsung Display Co., Ltd.

Daewoong Pharmaceutical Co., Ltd.

Min Ju Kim

Hee Jeong Seo

Eun-Jung Park

Kwang-Seop Song

Suk Ho Lee

Soongyu Choi

Younggyu Kong

Mi-Soon Kim

So Ok Park

Myung Eun Jung

Jinhwa Lee

Jeongmin Kim

Hyun Jung Kim

Min Woo Lee

Young Eun Ryu

Taek Kyo Kang

Jeong Ho Lee

Suk Hoon Kang

Kisoo Park

Sang Hun Lee

Ae Nim Pae

Se-Hwan Park

Woo-Kyu Park

Min Goo Kang

Sung-Han Lee

Minwoo Lee

Sang Woo Lee

Jung Woo Ko

Dong Hyuk Jang

Keun Soo Lee

Jae Eun Kim

Won Ho Kim

Young Seo Choi

Jae Suk Moon

Soo Hyun Min

Jong Yup Kim

Ickhwan Son

Man-Young Cha

Eun Jung Son

Kinam Lee

Hyunku Kang

Jun Sung Lee

Dong Ho Hong

Za Il Lhee

Hee-kyoon Yoon

Sang-ho Ma

Ji-sung Yoon

Sang Mi Kang

Ho Kyun Han

Su Cheol Gong

Jangwon Hong

Misuk Kang

Sang Hun Oh

Junwon Lee

Ki-Nam Lee

Sung Jin Kim

Ju Mi Hong

Kwang Seop Song

Kwang Woo Ahn

Suk Youn Kang

Jung Eun Kim

Jin Hyuk Kim

Young Don Park

Young Bin Baek

Ji-Sung Yoon

Hee-Kyoon Yoon

A mask assembly includes: a mask frame; a mask supported by the mask frame, the mask including a plurality of pattern holes; and a magnetic part disposed on one surface of the mask. The magnetic part provides a magnetic force between the mask and a target substrate and improves an adhesion between the mask and the target substrate to prevent deposition defects.

Mask assembly, deposition apparatus including the same, and fabricating method of the mask assembly

A display device includes: a base substrate including an active area, and a non-active area including a crack dam arrangement area; a plurality of inorganic layers on the base substrate; and an encapsulation layer on the plurality of inorganic layers, and including an encapsulation inorganic layer, and an encapsulation organic layer on the encapsulation inorganic layer. The base substrate includes first substrate portions having a first thickness at the crack dam arrangement area, and a second substrate portion between adjacent ones of the first substrate portions and connected to the first substrate portions, the second substrate portion having a second thickness smaller than the first thickness. The plurality of inorganic layers are laminated to form an inorganic laminated film at the crack dam arrangement area; and the encapsulation inorganic layer is located over the first substrate portions and the second substrate portion, and includes at least one short circuit portion.

Display device including encapsulation organic layer on base substrate having different thicknesses at non-active area

Display device including crack dam arrangement area

A mask and a method of manufacturing a mask assembly, the mask including a body, and the body including one end and another end facing each other in a length direction and having a first surface and a second surface facing each other in a thickness direction; and a pattern region between the one end and the other end, the pattern region including a plurality of pattern holes and a plurality of ribs between the plurality of pattern holes, wherein a curl value of the mask, which is defined as a shortest distance from a plane tangent to a center of the body to the one end or the other end of the body, is 1,000 &#x3bc;m to 4,000 &#x3bc;m.

Mask and method of manufacturing mask assembly including the same

A flexible organic light-emitting display device may include: a first polymer layer; a first transparent conductive layer over the first polymer layer; a first inorganic layer over the first transparent conductive layer; and a plurality of pixels on the first inorganic layer and each including an organic light-emitting diode, and a driver configured to drive the organic light-emitting diode.

Flexible substrate and display device including the same

The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.

Method for producing diphenylmethane derivative

Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK&#x3b5; (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK&#x3b5; and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Pyrazole derivatives as TNIK, IKK&#x3f5; and TBK1 inhibitor and pharmaceutical composition comprising same

Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK&#x3b5; (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK&#x3b5; and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

7-azaindole or 4,7-diazaindole derivatives as IKK&#x3f5; epsilon and TBK1 inhibitor and pharmaceutical composition comprising same

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

Diphenylmethane derivatives as SGLT2 inhibitors

The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.

Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives

Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.

[object Object]

Growing community of inventors

Yongin-si, South Korea

Min Ju Kim